Regarding “Prospective, randomized study of cutting balloon angioplasty versus conventional balloon angioplasty for the treatment of hemodialysis access stenoses”  by Neuen, Brendon L. et al.
JOURNAL OF VASCULAR SURGERY
1122 Letters to the Editor October 2014repair. The latter perhaps may be due to patient preference, clinical
deterioration, or severe comorbid conditions that preclude survival
even with attempted repair.
We believe that the transfer process for rAAA can be improved
to ensure optimal outcomes with efﬁcient utilization of resources.
Potential strategies include improvements in the transfer process,
as outlined by Dr Altreuther, as well as improved guidelines to
identify patients whose survival is unlikely and for whom care mea-
sures other than transfer may be considered.
Matthew Mell, MD
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Regarding “Prospective, randomized study of cutting
balloon angioplasty versus conventional balloon
angioplasty for the treatment of hemodialysis access
stenoses”
In their recently reported randomized trial, Saleh et al found
that cutting balloon angioplasty improved treatment area pri-
mary patency of graft-vein anastomotic lesions at 6 and 12
months compared with conventional balloon angioplasty.1 How-
ever, for lesions at other locations treated with cutting balloons,
there was no beneﬁt over conventional angioplasty. We believe
the study has several important limitations that require further
discussion.
The study included both native arteriovenous ﬁstulas (AVFs)
and prosthetic grafts, but it is well established that prosthetic grafts
require more interventions to maintain patency than AVFs do.2
These two scenarios have vastly differing pathologic processes
and outcomes and cannot be grouped as if similar. Reporting
the proportion of native AVFs and grafts in the study and sub-
group analysis separating both types of access would provide addi-
tional important information.
Saleh et al classify lesion location into four categories:
venous, graft-to-vein anastomotic, intragraft, and arterial anasto-
motic. In native AVFs, only two of these categories apply. In such
cases, venous refers to all lesions from the arteriovenous anasto-
mosis to the cephalic arch. The terminal portion of the cephalic
vein is particularly prone to restenosis after conventional angio-
plasty and is, in and of itself, an area of research interest. Obser-
vational studies also suggest that lesion length and angioplasty in
newer AVFs may also be associated with higher rates of resteno-
sis.3 Information on access age, lesion characteristics, and com-
parison of patency at other speciﬁc venous locations might
generate additional hypotheses on the indications for cutting
balloon use.
Cumulative or secondary patency (ie, the time from initial
angioplasty until the access is abandoned) is the most important
outcome for patients as it represents the functional life of the ac-
cess. However, the authors do not report this outcome; instead,
the main patency deﬁnition used is treatment area primary
patency. Reporting access circuit primary patency (ie, the time
from initial angioplasty to repeated endovascular intervention
for any lesion in the access circuit) is mandatory and ultimately
more important than isolated lesion primary patency. Thrombosisleading to access loss is important because of the potential for
exposure of the patient to mortality risk associated with central
venous catheters. Freedom from access interventions is another
important measure of quality of life for hemodialysis patients.
None of these clinically meaningful end points are measured or
reported in the trial.
This study is timely, given the increasingly strong evidence sup-
porting the use of stent grafts in many of these scenarios, such as the
original FLAIR trial and presented results of REVISE and REN-
OVA, all randomized trials demonstrating graft preservation supe-
rior to angioplasty to 2 years.4 One other recent study, by Aftab
et al, suggested the utility of cutting balloon compared with angio-
plasty in AVFs,5 although Vesely and Siegel’s larger trial in pros-
thetic grafts did not.6 Given these mixed messages and limits of
presented data within the current study, we believe that the study
by Saleh et al does not support the widespread use of cutting
balloon angioplasty for dialysis access stenosis.
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Regarding “Management of acute limb ischemia in the
pediatric population”
Peripheral vascular injuries of the lower extremity in the pedi-
atric population are rare but can result in signiﬁcant morbidity.
These injuries are usually iatrogenic after catheterization or inva-
sive monitoring. Pediatric peripheral vascular trauma is far less
frequent, and there is scarcity of reported experience with
